SGO 2019: Niraparib Maintains Remission and Extends Symptom-Free Interval in Recurrent Ovarian Cancer
Patients who received niraparib as maintenance therapy experienced a longer symptom-free interval than those who received placebo.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.